ZOGENIX, INC. Balance Sheet | Understand Stock

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD; shares in millions, except per-share amounts

	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017
Assets
Current assets:
Cash and cash equivalents
Marketable securities
Other receivable
Accounts receivable, net
Inventory
Prepaid expenses
Acquisition holdback placed in escrow
Other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Indefinite-lived intangible assets
Intangible asset, net
Goodwill
Other non-current assets
Total assets
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
Accrued clinical trial expenses
Accrued compensation
Working capital advance note payable, net of discount of $3,733 at December 31, 2016
Current portion of long-term debt
Deferred revenue
Current liabilities of discontinued operations
Other Accrued Liabilities, Current
Accrued and other current liabilities
Acquisition holdback liability
Deferred revenue, current
Current portion of operating lease liabilities
Current portion of contingent consideration
Common stock warrant liabilities
Total current liabilities
Deferred revenue, noncurrent
Deferred revenue, non-current

Operating lease liabilities, net of current portion
Contingent consideration, net of current portion
Deferred income taxes
Deferred tax liability
Other long-term liabilities
Deferred rent and lease incentive obligation
Convertible debt
Total liabilities
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000 shares authorized, none issued and outstanding
Common stock and additional paid-in capital, $0.001 par value: 200,000 and 100,000 shares authorized and 55,935 and 55,736 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively
Common stock, $0.001 par value; 200,000 and 100,000 shares authorized and 56,095 and 55,736 shares issued and outstanding at December 31, 2021 and 2020, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity

Common stock authorized (shares)

Comments